A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
Kenichiro ToritaniJun WatanabeYusuke SuwaKazuya NakagawaHirokazu SuwaAtsushi IshibeMitsuyoshi OtaChikara KunisakiTakeharu YamanakaItaru EndoPublished in: International journal of colorectal disease (2020)
Neoadjuvant chemotherapy of mFOLFOX6 plus panitumumab without radiotherapy resulted in a low pCR rate but a high PR rate, low local recurrence rate, and good long-term outcome, suggesting that this treatment strategy may be a viable option for patients unable or unwilling to receive radiotherapy. The trial was registered with the UMIN Clinical Trials Registry, number 000006039.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- rectal cancer
- phase ii study
- clinical trial
- metastatic colorectal cancer
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- sentinel lymph node
- phase iii
- phase ii
- study protocol
- chronic kidney disease
- ejection fraction
- newly diagnosed
- early stage
- peritoneal dialysis
- lymph node
- open label
- wild type
- prognostic factors
- cross sectional
- real time pcr